Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Growth Factors Identified for Current Orphan Drug Market

By BiotechDaily International staff writers
Posted on 08 Jul 2013
A new market research report by Kalorama Information (Rockville, MD, USA) identifies factors likely to have stimulated the current orphan drug market, with further growth expected for the next forecast period.

Drugs for treating rare conditions are commonly referred to as "orphan drugs." The global orphan drug market reached 61 billion in 2012, according to Kalorama. The new Kalorama report - "The World Market for Orphan Drugs" - states that the increasing incidence of diseases affecting the aged will drive the market to increase at a rate of 11.5% throughout the forecast period, reaching USD 105.2 billion by 2017. In the USA, the largest market, Congress determined that adequate therapies for many rare diseases had not been developed because companies could not expect an orphan drug to make sufficient profit; therefore, incentives were needed for developing such drugs. According to Kalorama, these incentives have worked, helping to create a thriving market for this sector of treatments.

The report breaks out the market by company and by category. Non-Hodgkin's lymphoma, multiple myeloma, renal disease, and osteoporosis are among the diseases where treatments are not sufficient, according to the report. "In these markets regulators have allowed new orphan therapies," said Bruce Carlson, publisher, Kalorama Information, "Pharmaceutical companies have seen an opportunity in developing drugs with reduced regulatory costs and incentivized development."

Kalorama's estimate relates to the market where only orphan drug-designation revenue is included. Other estimates may also include brand revenue not truly occurring from an orphan designation. A product available as an orphan drug in one country may be available under traditional marketing approval in another. Some products that gain orphan status are later granted approval and removed from the orphan drug database at the developer's request. Factors involved in also include reimbursement, regulation, disease status, and general development, all of which were taken into account in Kalorama's study.

The report also presents major and small pharmaceutical companies' activities within this drug category, their market share, and predicts leading market contributers.

Related Links:
Kalorama Information
Kalorama Orphan Drugs Report



view channel
Image: representation of a protein (blue), which contains three zinc fingers in complex with DNA (orange). The coordinating amino acid residues and zinc ions (green) are highlighted (Photo courtesy of Wikimedia Commons).

Molecular Sensors Generated by Synthetic Biology Technique Using Intein-Based Protein Splicing

Biotech researchers have used intein-based protein splicing to generate synthetic protein components that are able to detect specific DNA sequences and subsequently trigger a desired intracellular response... Read more

Drug Discovery

view channel
Image: Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places (Photo courtesy of Wikimedia Commons).

Orally Delivered Curcumin-Loaded Microparticles Effectively Treat Mouse Model of Ulcerative Colitis

Microparticles (MPs) loaded with the efficient anti-inflammatory agent curcumin were found to effectively treat a mouse model of ulcerative colitis. Ulcerative colitis is a chronic relapsing disease... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.